Therapeutic Asset Ratings

163 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Treg Cells Advanced Hematologic Malignancies	Stanford University	P2	B (56)
Relatlimab Brain Metastases	Stanford University	P2	CCC (55)
Talzenna Breast Cancer	Stanford University	P2	CCC (55)
Busulphan Multiple Sclerosis	Stanford University	P2	CCC (54)
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE Cluster Headache	Stanford University	P2	CCC (53)
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE Paroxysmal Hemicrania	Stanford University	P2	CCC (53)
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE Sphenopalatine Ganglion Neuralgia	Stanford University	P2	CCC (53)
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE Trigeminal Autonomic Cephalgia	Stanford University	P2	CCC (53)
(±)-2-(O-CHLOROPHENYL)-2-(METHYLAMINO)CYCLOHEXANONE Complex Regional Pain Syndromes	Stanford University	P2	CCC (53)
GLUCOSE, ANHYDROUS GBM	Stanford University	P2	CCC (53)
MIDAZOLAM Complex Regional Pain Syndromes	Stanford University	P2	CCC (53)
qbs72s Leptomeningeal Disease	Stanford University	P2	CCC (53)
qbs72s LMD	Stanford University	P2	CCC (53)
Talquetamab Post Stem Cell Transplant	Stanford University	P2	CCC (53)
Empagliflozin Sodium-Glucose Transporter 2 Inhibitors	Stanford University	P1	CCC (52)
GLUCOSE, ANHYDROUS Glioma	Stanford University	P2	CCC (51)
qbs72s Brain Metastases	Stanford University	P2	CCC (51)
Tisagenlecleucel Leukemia	Stanford University	P1/2	CCC (49)
Bumetanide Alzheimer Disease	Stanford University	P2	CCC (48)
qbs72s Lung Cancer	Stanford University	P2	CCC (48)
Treg Cells Acute Leukemia	Stanford University	P1/2	CCC (48)
FTC-146 Nociceptive Pain	Stanford University	P1	CC (47)
qbs72s Breast Cancer	Stanford University	P2	CC (46)
Empagliflozin Ascites	Stanford University	P1	CC (46)
Autologous T cells obtained from peripheral blood mononuclear cells by leukapheresis, transduced with a self-inactivating, nonreplicating lentiviral vector, encoding a T cell chimeric antigen receptor targeting CD19. The expressed transgene comprises a CD8? leader sequence, a murine anti-CD19 single chain variable fragment (scFv) derived from the mouse hybridoma FMC63, a CD8? hinge and transmembrane region, and a 4-1BB (CD137) and CD3? (TCR?) signaling domain and is under control of the elongation factor 1 alpha (EF1?) promoter. The construct is flanked by 5' and 3' long terminal repeats (LTRs) and also contains a ? packaging signal, a Rev response element (RRE), a central polypurine tract (cPPT) sequence and an optimized Woodchuck hepatitis virus posttranscriptional regulatory element (WPRE). The leukapheresis material is enriched for CD4/CD8 T cells by positive immunoselection, activated by CD3 and CD28 agonists and transduced with the vector. Without further cell propagation, the T cells are washed, formulated for infusion, and cryopreserved. The substance is composed of ?80% T cells and ?1% B cells, with a mixture of transgene positive (>3.4%) and negative T cells. The CD4+ and CD8+ naïve T cell subsets (CD45RA+CCR7+) present in the leukapheresis material are largely retained Large-cell Lymphoma	Stanford University	P1	CC (43)

Showing 76 to 100 of 163 assets

PreviousPage 4 of 7Next